Beneficial Effects of Aleglitazar on Cardioprotection in Human Cardiomyocytes Under Hypoxic and Diabetic Conditions

Project: Other project

StatusFinished
Effective start/end date2/22/121/3/16

Funding

  • F. Hoffmann-La Roche AG: $221,891.00